Abstract
Sublingual (S/L) buprenorphine is FDA approved only for treatment of opioid addiction (opioid detoxification and maintenance). Buprenorphine in patch form is approved only for analgesia. However, buprenorphine is present at a significantly lower dose in the patch form as compared to the S/L forms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Stahl SM. Buprenorphine. In: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2014. p. 87–90.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chow, R.M., Issa, M. (2017). Buprenorphine. In: Yong, R., Nguyen, M., Nelson, E., Urman, R. (eds) Pain Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-43133-8_39
Download citation
DOI: https://doi.org/10.1007/978-3-319-43133-8_39
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43131-4
Online ISBN: 978-3-319-43133-8
eBook Packages: MedicineMedicine (R0)